Interpace Diagnostics to Attend and Present at the 8th Annual LD Micro Invitational Conference
June 04 2018 - 8:30AM
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” or
“the Company”), a fully integrated commercial and bioinformatics
company that provides clinically useful molecular diagnostic tests
and pathology services for improved patient diagnosis and
management, today announced that Jack Stover, President and Chief
Executive Officer of Interpace, will be presenting at the 8th
Annual LD Micro Invitational Conference on June 4th, 2018 at 2:30
p.m. PT. The conference is being held at the Luxe Sunset Bel Air in
Los Angeles, CA from June 4th-6th.
What: Presentation at the 8th
Annual LD Micro Invitational ConferenceWhen:
Monday, June 4th, 2:30 p.m. PTWhere: Luxe Sunset
Bel Air, 11461 Sunset Blvd., Los Angeles, CA 90049
About Interpace Diagnostics Group,
Inc.
Interpace is a fully integrated commercial and
bioinformatics company that provides clinically useful molecular
diagnostic tests and pathology services for evaluating risk of
cancer by leveraging the latest technology in personalized medicine
for improved patient diagnosis and management. The Company
currently has four commercialized molecular tests and one test in a
clinical evaluation process (CEP); PancraGEN® for the diagnosis and
prognosis of pancreatic cancer from pancreatic cysts; ThyGenX® for
the diagnosis of thyroid cancer from thyroid nodules utilizing a
next generation sequencing assay; ThyraMIR™ for the diagnosis of
thyroid cancer from thyroid nodules utilizing a proprietary gene
expression assay; and RespriDX® that differentiates lung cancer of
primary vs. metastatic origin. BarreGEN® for Barrett's Esophagus,
is currently being “soft launched” with key opinion leaders as we
continue to gather data on this assay that will assist us in
seeking favorable reimbursement as well as important clinical
information. Barrett's Esophagus is a rapidly growing diagnosis
that affects over three million people in the US and over time can
progress to esophageal cancer. The Company’s data base includes
data from over 45,000 patients who have been tested using the
Company’s current products, including over 15,000 molecular tests
for thyroid nodules. Interpace has been designated as one of the
top 20 companies for providing bioinformatics solutions.
Interpace’s mission is to provide personalized medicine through
molecular diagnostics, innovation and data to advance patient care
based on rigorous science. For more information, please visit
Interpace’s website at www.interpacediagnostics.com
Forward Looking Statements
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, relating to the
Company's future financial and operating performance, competitive
and market conditions and future business decisions, all of which
are difficult or impossible to predict accurately and many of which
are beyond the Company's control. These statements also involve
known and unknown risks, uncertainties and other factors that may
cause the Company's actual results to be materially different from
those expressed or implied by any forward-looking statement. Known
and unknown risks, uncertainties and other factors include, but are
not limited to, the Company’s history of losses, the Company's
ability to adequately finance the business, the market's acceptance
of its molecular diagnostic tests, its ability to retain or secure
reimbursement, its ability to secure additional business and
generate higher profit margins through sales of its molecular
diagnostic tests, in-licensing or other means, projections of
future revenues, growth, gross profit and anticipated internal rate
of return on investments and its ability to maintain its NASDAQ
listing. Additionally, all forward-looking statements are subject
to the “Risk Factors” detailed from time to time in the Company's
SEC filings, including its Annual Report on Form 10-K for the
fiscal year ended December 31, 2017, filed on March 23, 2018,
Quarterly Reports on Form 10-Q and other SEC filings.
Because of these and other risks, uncertainties
and assumptions, undue reliance should not be placed on these
forward-looking statements. In addition, these statements speak
only as of the date of this press release and, except as may be
required by law, the Company undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.
Contact
Interpace DiagnosticsInvestor Relations:
Joe Green – Edison Group(646)
653-7030jgreen@edisongroup.com
Andrew Gibson – Edison Group (On Site)(646)
653-7719agibson@edisongroup.com
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Mar 2024 to Apr 2024
Interpace Biosciences (NASDAQ:IDXG)
Historical Stock Chart
From Apr 2023 to Apr 2024